ArticleFrontiers in immunology2022

Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.

Hao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.